Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The SENTRY Clinical Study (SENTRY)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Novate Medical Identifier:
First received: October 28, 2013
Last updated: March 2, 2016
Last verified: March 2016

October 28, 2013
March 2, 2016
September 2014
August 2016   (final data collection date for primary outcome measure)
Clinical Success Rate of the Sentry IVC Filter [ Time Frame: 6 Months ] [ Designated as safety issue: Yes ]

A Composite Endpoint including:

Technical success in deployment without acute Events; Freedom from Symptomatic Pulmonary Embolism; and Freedom from IVC filter related complications

Same as current
Complete list of historical versions of study NCT01975090 on Archive Site
(1) Technical Success (2) Filter Status (3) Symptomatic PE (4) Freedom from IVC filter related complications [ Time Frame: 1, 2, 6 and 12 Months ] [ Designated as safety issue: Yes ]
IVC filter related complications include, filter tilting, migration, embolization, fracture, vessel perforation, symptomatic caval thrombosis, invasive filter intervention and filter-related death.
Same as current
(1) New Symptomatic DVT(5) Procedure related serious adverse events (SAE) (2) New or symptomatic venous thromboembolism [ Time Frame: 1, 2, 6 and 12 Months ] [ Designated as safety issue: Yes ]
Same as current
The SENTRY Clinical Study
A Prospective, Multi-Center Study of the Novate Sentry Bioconvertible Vena Cava Filter
The SENTRY Bioconvertible Inferior Vena Cava (IVC) Filter has been developed to provide temporary protection against pulmonary embolism (PE).

Pulmonary embolism (PE) is a prevalent disease with a significant morbidity and mortality. The estimated annual incidence is 1.45 per 1,000 patients, which translates to 1,350,000 cases per year in the United States. It is estimated that PE results in more than 200,000 deaths per year.

Currently there are two types of commercially available IVC filters utilized to prevent PE; permanent and retrievable. Both types of filters have documented limitations, such as tilting, migration, fracture, embolization and late deep vein thrombosis (DVT). Retrievable filters were developed to avert some of the late consequences of permanent filter, but in practice there is low success with eventual removal. In a series of 37 clinical studies, with a total of 6,834 patients the mean retrieval rate was 34%.

There are numerous design features of the SENTRY IVC Filter that are intended to improve on the limitations of available IVC filters and obviate the need for retrieval.

Not Provided
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
  • Pulmonary Embolism
  • Deep Vein Thrombosis
Device: SENTRY IVC Filter
The SENTRY IVC Bioconvertible Filter is designed to provide temporary protection to subjects at transient, high risk of pulmonary embolism. Following conclusion of the protection period The SENTRY filter bioconverts, and filter arms withdraw towards the IVC wall for incorporation; obviating the need for retrieval.
Experimental: SENTRY IVC Filter
The SENTRY IVC Bioconvertible Filter
Intervention: Device: SENTRY IVC Filter

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
February 2017
August 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. > 18 years of age
  2. fully informed subject who has executed an Institutional Review Board (IRB) or Ethics Committee (EC) approved informed consent
  3. willing and able to comply with follow-up visit requirements
  4. requirement of transient PE protection of < 60 days
  5. documented or high risk of PE or DVT
  6. inability to use anti-coagulation due to contraindication, failure, complication or risk of injury from pharmacotherapy
  7. IVC diameter compatible with filter diameter
  8. IVC length adequate for filter placement

Exclusion Criteria:

  1. intellectual impairment preventing understanding involvement in a clinical study
  2. hypersensitivity to device components
  3. impaired renal function defined as a serum creatinine level of > 2.0 mg/dL
  4. active systemic infection
  5. life expectancy < 12 months
  6. malignancy extending PE risk > 60 days
  7. pregnant or plans to become pregnant during study follow-up period
  8. participating in another investigational trial that has not reached its primary endpoint
  9. known hypercoaguable state
  10. inherited or acquired hemostatic disorder
  11. history or presence of a caval stent or filter
  12. inability to gain femoral or jugular access
  13. duplicated or left sided IVC
  14. renal vein thrombosis or IVC thrombosis extending to the renal veins
  15. jugular and femoral vein irregularity, stenosis or aneurysm that would interfere with successful device delivery
  16. spinal irregularity that may interfere with successful device delivery
  17. occlusive or free-floating thrombus in the IVC
  18. contrast allergy that cannot be adequately pre-medicated
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States,   Belgium,   Chile
CI 036
Not Provided
Not Provided
Novate Medical
Novate Medical
Not Provided
Principal Investigator: Michael D Dake, MD Stanford University
Novate Medical
March 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP